These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 15860893)
1. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. De Preter K; Speleman F; Combaret V; Lunec J; Board J; Pearson A; De Paepe A; Van Roy N; Laureys G; Vandesompele J J Clin Oncol; 2005 May; 23(13):3167-8; author reply 3168-70. PubMed ID: 15860893 [No Abstract] [Full Text] [Related]
2. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. Weber A; Imisch P; Bergmann E; Christiansen H J Clin Oncol; 2004 Jul; 22(13):2681-90. PubMed ID: 15226335 [TBL] [Abstract][Full Text] [Related]
3. Concomitant DDX1 and MYCN gain in neuroblastoma. Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020 [TBL] [Abstract][Full Text] [Related]
4. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693 [TBL] [Abstract][Full Text] [Related]
5. Expression of two dead box genes (DDX1 and DDX6) is independent of that of MYCN in human neuroblastoma cell lines. Akiyama K; Akao Y; Yokoyama M; Nakagawa Y; Noguchi T; Yagi K; Nishi Y Biochem Mol Biol Int; 1999 Apr; 47(4):563-8. PubMed ID: 10319407 [TBL] [Abstract][Full Text] [Related]
6. Amplification of a DEAD box gene (DDX1) with the MYCN gene in neuroblastomas as a result of cosegregation of sequences flanking the MYCN locus. Noguchi T; Akiyama K; Yokoyama M; Kanda N; Matsunaga T; Nishi Y Genes Chromosomes Cancer; 1996 Feb; 15(2):129-33. PubMed ID: 8834177 [TBL] [Abstract][Full Text] [Related]
7. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma. Amler LC; Schürmann J; Schwab M Genes Chromosomes Cancer; 1996 Feb; 15(2):134-7. PubMed ID: 8834178 [TBL] [Abstract][Full Text] [Related]
8. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group. George RE; Kenyon RM; McGuckin AG; Malcolm AJ; Pearson AD; Lunec J Oncogene; 1996 Apr; 12(7):1583-7. PubMed ID: 8622876 [TBL] [Abstract][Full Text] [Related]
9. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906 [TBL] [Abstract][Full Text] [Related]
10. Physical mapping of the DDX1 gene to 340 kb 5' of MYCN. Kuroda H; White PS; Sulman EP; Manohar CF; Reiter JL; Cohn SL; Brodeur GM Oncogene; 1996 Oct; 13(7):1561-5. PubMed ID: 8875996 [TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma. de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590 [TBL] [Abstract][Full Text] [Related]
12. Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype? Scott D; Elsden J; Pearson A; Lunec J Cancer Lett; 2003 Jul; 197(1-2):81-6. PubMed ID: 12880964 [TBL] [Abstract][Full Text] [Related]
13. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. De Preter K; Speleman F; Combaret V; Lunec J; Laureys G; Eussen BH; Francotte N; Board J; Pearson AD; De Paepe A; Van Roy N; Vandesompele J Mod Pathol; 2002 Feb; 15(2):159-66. PubMed ID: 11850545 [TBL] [Abstract][Full Text] [Related]
14. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664 [TBL] [Abstract][Full Text] [Related]
16. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Combaret V; Audoynaud C; Iacono I; Favrot MC; Schell M; Bergeron C; Puisieux A Cancer Res; 2002 Jul; 62(13):3646-8. PubMed ID: 12097268 [TBL] [Abstract][Full Text] [Related]
17. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915 [TBL] [Abstract][Full Text] [Related]
18. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy. Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185 [TBL] [Abstract][Full Text] [Related]
19. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714 [TBL] [Abstract][Full Text] [Related]
20. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology. Schwab M Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]